Cyprotex agrees new partnership deal

CYPROTEX  has announced a strategic alliance with Siruis Analytical Instruments which the pair say will strengthen physicochemical profiling services.

The physicochemical properties of a drug can influence its absorption and distribution into tissues, as well as the drug’s binding characteristics.

Macclesfield-based Cyprotex said that Sirius’s instrumentation is the most reliable in the market, which can measure physicochemical properties using small, often sub-milligram, quantities of material.

As a result, combining this with its own ADME-Tox services should help the firm to offer a broader range of services to determine a drug compound’s efficacy and its toxicology.

Dr. Anthony Baxter, Cyprotex’s chief executive dfficer, said: “Physicochemical property determination is key to our understanding of how a drug behaves in the body.  The properties are used routinely in prediction methods and feature in our PBPK modelling software, Cloe® PK.  

“Sirius have an impressive record of over 20 years expertise in this specialist field.  By partnering with Sirius, Cyprotex customers will have access to a broader range of expert services which complement our existing portfolio of ADME-Tox services.”